Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours.
M K
MK
Krzyzanowska
M S
MS
Tsao
A M
AM
Oza
M
M
Haider
R
R
Feld
J
J
Knox
S
S
Chin
H
H
Hu
L L
LL
Siu
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000069287:Capecitabine; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D013450:Sulfones / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000964:Antimetabolites, Antineoplastic; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D003841:Deoxycytidine; D000069287:Capecitabine; D051546:Cyclooxygenase 2; D005472:Fluorouracil